- Home
- BV vs DVAX Comparison
BV vs DVAX Comparison
Compare BV & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BV
- DVAX
- Stock Information
- Founded
- BV 1939
- DVAX 1996
- Country
- BV United States
- DVAX United States
- Employees
- BV N/A
- DVAX N/A
- Industry
- BV Business Services
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- BV Consumer Discretionary
- DVAX Health Care
- Exchange
- BV Nasdaq
- DVAX Nasdaq
- Market Cap
- BV 1.4B
- DVAX 1.3B
- IPO Year
- BV 2018
- DVAX 2004
- Fundamental
- Price
- BV $14.66
- DVAX $10.26
- Analyst Decision
- BV Buy
- DVAX Buy
- Analyst Count
- BV 7
- DVAX 4
- Target Price
- BV $17.82
- DVAX $26.50
- AVG Volume (30 Days)
- BV 900.9K
- DVAX 1.7M
- Earning Date
- BV 08-06-2025
- DVAX 08-07-2025
- Dividend Yield
- BV N/A
- DVAX N/A
- EPS Growth
- BV N/A
- DVAX N/A
- EPS
- BV 0.12
- DVAX N/A
- Revenue
- BV $2,698,700,000.00
- DVAX $316,268,000.00
- Revenue This Year
- BV $1.19
- DVAX $23.23
- Revenue Next Year
- BV $3.14
- DVAX $16.57
- P/E Ratio
- BV $121.72
- DVAX N/A
- Revenue Growth
- BV N/A
- DVAX 26.66
- 52 Week Low
- BV $11.81
- DVAX $9.22
- 52 Week High
- BV $18.89
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- BV 40.92
- DVAX 44.20
- Support Level
- BV $14.45
- DVAX $10.27
- Resistance Level
- BV $15.25
- DVAX $11.45
- Average True Range (ATR)
- BV 0.39
- DVAX 0.44
- MACD
- BV -0.02
- DVAX -0.05
- Stochastic Oscillator
- BV 20.96
- DVAX 24.09
About BV BrightView Holdings Inc.
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.